Cedecea Davisae Bacteraemia After Tocilizumab Usage for Coronavirus Disease 2019 Treatment

Abstract

Cedecea davisae (C. davisae) is a Gram-negative, non-sporulating, motile rod-shaped bacterium of the Enterobacteriaceae family. Cedecea are new members of the Enterobacteriaceae family. Because of their inherent resistance to some antibiotics, the clinical response could be unpredictable, making the management of Cedecea infection challenging in immunocompromised patients. They have rarely been reported as causes of invasive infection. Cedecea can cause opportunistic infections in elderly patients. To the best of our knowledge, only 13 cases of C. davisae bacteraemia have been reported in literature. In this article, we report a case of C. davisae bacteraemia developed after the usage of tocilizumab for coronavirus disease-2019 treatment. A brief review of the literature is also presented in this article. (English) [ABSTRACT FROM AUTHOR] Cedecea davisae (C. davisae) Gram-negatif, sporsuz, haraketli, çubuk şeklinde Enterobacteriaceae ailesine ait bir bakteridir. Cedecea, Enterobacteriaceae ailesinin yeni üyelerindendir. Bazı antibiyotiklere karşı doğal dirençleri nedeniyle, klinik cevap öngörülemez olabilir, bu da immünosüprese hastalarda Cedecea enfeksiyonunun yönetimini zorlaştırır. Nadiren invaziv enfeksiyonun nedeni olarak bildirilmiştir. Íleri yaştaki hastalarda fırsatçı enfeksiyonlara neden olabilir. Bildiğimiz kadarıyla literatürde sadece 13 C. davisae bakteriyemi olgusu bildirilmiştir. Bu makalede, koronavirüs hastalığı-2019 tedavisinde kullanılan tosiluzumab sonrası gelişen C. davisae bakteriyemi olgusu ve ardından literatürün kısa bir derlemesi sunulmaktadır. (Turkish) [ABSTRACT FROM AUTHOR] Copyright of Turkish Journal of Intensive Care is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)